PROM1 and non-small cell lung carcinoma: To overcome the limited access to patient-derived tumor cells and to directly detect the lipogenesis activity in patient-derived CSCs, organoids (PDOs) derived from patients with NSCLC were established, followed by analyses of CD133-expressing tumor cells.